Creo Medical Group PLC (AIM:CREO)
London · Delayed Price · Currency is GBP · Price in GBX 11.25
0.00 (0.00%)
Oct 10, 2025, 4:38 PM GMT+1
Creo Medical Group Income Statement
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 4.6 | 4 | 4 | 27.2 | 25.16 | 9.43 | Upgrade |
| 4.6 | 4 | 4 | 27.2 | 25.16 | 9.43 | Upgrade | |
Revenue Growth (YoY) | - | - | -85.29% | 8.10% | 166.85% | 69884.41% | Upgrade |
Cost of Revenue | 2.5 | 2.1 | 1.7 | 14 | 13.58 | 5.39 | Upgrade |
Gross Profit | 2.1 | 1.9 | 2.3 | 13.2 | 11.59 | 4.04 | Upgrade |
Selling, General & Admin | 24.7 | 29.2 | 29.1 | 44 | 41.54 | 27.57 | Upgrade |
Other Operating Expenses | 0.4 | 0.4 | -0.4 | -0.1 | -0.05 | -0.05 | Upgrade |
Operating Expenses | 25.1 | 29.6 | 28.7 | 43.9 | 41.49 | 27.52 | Upgrade |
Operating Income | -23 | -27.7 | -26.4 | -30.7 | -29.91 | -23.48 | Upgrade |
Interest Expense | -0.4 | -0.4 | -0.2 | -0.2 | -0.21 | -0.07 | Upgrade |
Interest & Investment Income | 0.4 | 0.2 | 0.7 | 0.1 | 0.03 | 0.18 | Upgrade |
Other Non Operating Income (Expenses) | - | - | - | -0.1 | -0.25 | -0.09 | Upgrade |
EBT Excluding Unusual Items | -23.3 | -27.9 | -25.9 | -30.9 | -30.34 | -23.46 | Upgrade |
Merger & Restructuring Charges | -1.1 | -1.1 | - | - | - | - | Upgrade |
Other Unusual Items | 0.1 | - | -0.5 | - | - | - | Upgrade |
Pretax Income | 1.9 | -29 | -26.4 | -30.9 | -30.34 | -23.46 | Upgrade |
Income Tax Expense | -0.7 | -1.2 | -2.7 | -4 | -5.74 | -3.15 | Upgrade |
Earnings From Continuing Operations | 2.6 | -27.8 | -23.7 | -26.9 | -24.6 | -20.32 | Upgrade |
Earnings From Discontinued Operations | -2.1 | -0.9 | 2 | - | - | - | Upgrade |
Net Income | 0.5 | -28.7 | -21.7 | -26.9 | -24.6 | -20.32 | Upgrade |
Net Income to Common | 0.5 | -28.7 | -21.7 | -26.9 | -24.6 | -20.32 | Upgrade |
Shares Outstanding (Basic) | 396 | 370 | 313 | 181 | 164 | 156 | Upgrade |
Shares Outstanding (Diluted) | 397 | 370 | 313 | 181 | 164 | 156 | Upgrade |
Shares Change (YoY) | 17.86% | 18.20% | 72.61% | 10.28% | 5.54% | 28.39% | Upgrade |
EPS (Basic) | 0.00 | -0.08 | -0.07 | -0.15 | -0.15 | -0.13 | Upgrade |
EPS (Diluted) | -0.00 | -0.08 | -0.07 | -0.15 | -0.15 | -0.13 | Upgrade |
Free Cash Flow | 7 | -22.5 | -22.8 | -28.1 | -31.99 | -16.77 | Upgrade |
Free Cash Flow Per Share | 0.02 | -0.06 | -0.07 | -0.15 | -0.20 | -0.11 | Upgrade |
Gross Margin | 45.65% | 47.50% | 57.50% | 48.53% | 46.04% | 42.79% | Upgrade |
Operating Margin | -500.00% | -692.50% | -660.00% | -112.87% | -118.86% | -249.06% | Upgrade |
Profit Margin | 10.87% | -717.50% | -542.50% | -98.90% | -97.75% | -215.46% | Upgrade |
Free Cash Flow Margin | 152.17% | -562.50% | -570.00% | -103.31% | -127.13% | -177.80% | Upgrade |
EBITDA | -23.3 | -26.7 | -24.7 | -28.5 | -28.15 | -22.49 | Upgrade |
EBITDA Margin | - | - | - | -104.78% | -111.88% | -238.54% | Upgrade |
D&A For EBITDA | -0.3 | 1 | 1.7 | 2.2 | 1.76 | 0.99 | Upgrade |
EBIT | -23 | -27.7 | -26.4 | -30.7 | -29.91 | -23.48 | Upgrade |
EBIT Margin | - | - | - | -112.87% | -118.86% | -249.06% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.